Difference between revisions of "Part:BBa K5382110:Design"
Chenyuyanyan (Talk | contribs) |
Chenyuyanyan (Talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
===Design Notes=== | ===Design Notes=== | ||
| − | The two amino acid substitution of the z domain relative to the B domain is key, which may affect its binding affinity and specificity to IgG. The plasmid construction and introduction of | + | The two amino acid substitution of the z domain relative to the B domain is key, which may affect its binding affinity and specificity to IgG. The plasmid construction and introduction of InaK-linker-z domain as well as the amount of final expression also need to be detected and controlled, including the subsequent purification steps.The experimental design of this part is another direction of our project, the plasmid has been successfully constructed, and the subsequent experiments are ongoing.<Br> |
===Source=== | ===Source=== | ||
| − | The InaK is a protein derived from Pseudomonas syringae KCTC1832, an ice nucleated protein.<Br> | + | The InaK is a protein derived from <i>Pseudomonas syringae</i> KCTC1832, an ice nucleated protein.<Br> |
The linker is composed of Gly and Ser.<Br> | The linker is composed of Gly and Ser.<Br> | ||
| − | The z domain is derived from the B domain of protein A[1]. Protein A is a protein widely found on the cell wall of Staphylococcus aureus. The extracellular portion of protein A contains five highly homologous IgG binding domains, named E, D, A, B, and C from the N-terminal, each domain contains about 58 amino acid residues. The z domain is an engineered analogue of the B domain, originally developed as an affinity purification treatment for fusion protein production. In contrast to the B domain, the z domain contains two amino acid substitutes (Ala1→Val and Gly29→Ala). | + | The z domain is derived from the B domain of protein A<sup>[1]</sup>. Protein A is a protein widely found on the cell wall of Staphylococcus aureus. The extracellular portion of protein A contains five highly homologous IgG binding domains, named E, D, A, B, and C from the N-terminal, each domain contains about 58 amino acid residues. The z domain is an engineered analogue of the B domain, originally developed as an affinity purification treatment for fusion protein production. In contrast to the B domain, the z domain contains two amino acid substitutes (Ala1→Val and Gly29→Ala). |
===References=== | ===References=== | ||
[1] Oscar P B Wiklander;Doste R Mamand;Dara K Mohammad;Wenyi Zheng;Rim Jawad Wiklander;Taras Sych;Antje M Zickler;Xiuming Liang;Heena Sharma;Andrea Lavado;Jeremy Bost;Samantha Roudi;Giulia Corso;Angus J Lennaárd;Manuchehr Abedi Valugerdi;Imre Mäger;Evren Alici;Erdinc Sezgin;Joel Z Nordin;Dhanu Gupta;André Görgens;Samir El Andaloussi.Antibody-displaying extracellular vesicles for targeted cancer therapy.[J].Nature biomedical engineering,2024,() | [1] Oscar P B Wiklander;Doste R Mamand;Dara K Mohammad;Wenyi Zheng;Rim Jawad Wiklander;Taras Sych;Antje M Zickler;Xiuming Liang;Heena Sharma;Andrea Lavado;Jeremy Bost;Samantha Roudi;Giulia Corso;Angus J Lennaárd;Manuchehr Abedi Valugerdi;Imre Mäger;Evren Alici;Erdinc Sezgin;Joel Z Nordin;Dhanu Gupta;André Görgens;Samir El Andaloussi.Antibody-displaying extracellular vesicles for targeted cancer therapy.[J].Nature biomedical engineering,2024,() | ||
Latest revision as of 12:30, 2 October 2024
Inak-linker-z domain_protein domain that have the ability to bind to lgG
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 1674
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 722
Illegal NgoMIV site found at 962
Illegal NgoMIV site found at 1130
Illegal AgeI site found at 517 - 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI.rc site found at 692
Illegal BsaI.rc site found at 1182
Illegal SapI.rc site found at 326
Design Notes
The two amino acid substitution of the z domain relative to the B domain is key, which may affect its binding affinity and specificity to IgG. The plasmid construction and introduction of InaK-linker-z domain as well as the amount of final expression also need to be detected and controlled, including the subsequent purification steps.The experimental design of this part is another direction of our project, the plasmid has been successfully constructed, and the subsequent experiments are ongoing.
Source
The InaK is a protein derived from Pseudomonas syringae KCTC1832, an ice nucleated protein.
The linker is composed of Gly and Ser.
The z domain is derived from the B domain of protein A[1]. Protein A is a protein widely found on the cell wall of Staphylococcus aureus. The extracellular portion of protein A contains five highly homologous IgG binding domains, named E, D, A, B, and C from the N-terminal, each domain contains about 58 amino acid residues. The z domain is an engineered analogue of the B domain, originally developed as an affinity purification treatment for fusion protein production. In contrast to the B domain, the z domain contains two amino acid substitutes (Ala1→Val and Gly29→Ala).
References
[1] Oscar P B Wiklander;Doste R Mamand;Dara K Mohammad;Wenyi Zheng;Rim Jawad Wiklander;Taras Sych;Antje M Zickler;Xiuming Liang;Heena Sharma;Andrea Lavado;Jeremy Bost;Samantha Roudi;Giulia Corso;Angus J Lennaárd;Manuchehr Abedi Valugerdi;Imre Mäger;Evren Alici;Erdinc Sezgin;Joel Z Nordin;Dhanu Gupta;André Görgens;Samir El Andaloussi.Antibody-displaying extracellular vesicles for targeted cancer therapy.[J].Nature biomedical engineering,2024,()